Actinium Pharmaceuticals, Inc. (ATNM)

1.780.01 (-0.56%)

Actinium Pharmaceuticals, Inc. (ATNM) stock comprehensive Financial Growth Analysis including revenue, gross profit, operating profit, net profit, EPS, and other financial metrics. Compare financial growth against peers/competitors, industry and sector standards.

High Bankruptcy RiskBelow Average ESGFair ValuationLow ProfitabilityAdequate Financial HealthInefficient OperationsModerate GrowthLow QualityAdequate Dividend ProfileIndustry Rank: 20.71%Sector Rank: 20.23%

AMEX - Healthcare - Biotechnology | Market Cap: 55.53M | Next Earnings Date: 13 Nov 2025

Day's Range

1.75 - 1.81

52-Week Range

1.03 - 2.41

Volume

122.5K / 297.6K (Avg.)

P/E Ratio | EPS

-1.36 | -1.31

Trending:

ATNM Financial Growth Analysis - Compare Against TRAW

Comparison against TRAW

None AGEN AVXL RVPH AXSM TRAW

Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.

Revenue Growth

No Data

No Data available this quarter, please select a different quarter.

Gross Profit Growth

No Data

No Data available this quarter, please select a different quarter.

EBIT Growth

-2634.20%

Decreased from previous period

Negative EBIT growth while TRAW is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.

Operating Income Growth

-468.26%

Decreased from previous period

Negative operating income growth while TRAW is at 0.00%. Joel Greenblatt would press for urgent turnaround measures.

Net Income Growth

-263.73%

Decreased from previous period

Negative net income growth while TRAW stands at 0.00%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.

EPS Growth

-197.18%

Decreased from previous period

Negative EPS growth while TRAW is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.

Diluted EPS Growth

-197.18%

Decreased from previous period

Negative diluted EPS growth while TRAW is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.

Share Count Growth (Basic)

22.83%

Share change of 22.83% while TRAW is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.

Share Count Growth (Diluted)

22.83%

Diluted share change of 22.83% while TRAW is zero. Bruce Berkowitz might see a minor difference that could widen over time.

Dividend per Share Growth

No Data

No Data available this quarter, please select a different quarter.

Operating Cash Flow Growth

-36.01%

Decreased from previous period

Negative OCF growth while TRAW is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.

Free Cash Flow Growth

-62.21%

Decreased from previous period

Negative FCF growth while TRAW is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.

10-Year Revenue Growth per Share (CAGR)

No Data

No Data available this quarter, please select a different quarter.

5-Year Revenue Growth per Share (CAGR)

No Data

No Data available this quarter, please select a different quarter.

3-Year Revenue Growth per Share (CAGR)

No Data

No Data available this quarter, please select a different quarter.

10-Year Operating Cash Flow Growth per Share

-319.11%

Decreased from previous period

Negative 10Y OCF/share CAGR while TRAW stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.

5-Year Operating Cash Flow Growth per Share

-319.11%

Decreased from previous period

Negative 5Y OCF/share CAGR while TRAW is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.

3-Year Operating Cash Flow Growth per Share

52.30%

Increased from previous period

3Y OCF/share CAGR of 52.30% while TRAW is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.

10-Year Net Income Growth per Share

-5305.80%

Decreased from previous period

Negative 10Y net income/share CAGR while TRAW is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.

5-Year Net Income Growth per Share

-5305.80%

Decreased from previous period

Negative 5Y net income/share CAGR while TRAW is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.

3-Year Net Income Growth per Share

-47.53%

Decreased from previous period

Negative 3Y CAGR while TRAW is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.

10-Year Shareholders’ Equity Growth per Share

-1146.88%

Decreased from previous period

Negative equity/share CAGR over 10 years while TRAW stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.

5-Year Shareholders’ Equity Growth per Share

-1146.88%

Decreased from previous period

Negative 5Y equity/share growth while TRAW is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.

3-Year Shareholders’ Equity Growth per Share

3.51%

Increased from previous period

Equity/share CAGR of 3.51% while TRAW is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.

10-Year Dividend per Share Growth (CAGR)

No Data

No Data available this quarter, please select a different quarter.

5-Year Dividend per Share Growth (CAGR)

No Data

No Data available this quarter, please select a different quarter.

3-Year Dividend per Share Growth (CAGR)

No Data

No Data available this quarter, please select a different quarter.

Receivables Growth

-100.00%

Firm’s AR is declining while TRAW shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.

Inventory Growth

No Data

No Data available this quarter, please select a different quarter.

Asset Growth

No Data

No Data available this quarter, please select a different quarter.

Book Value per Share Growth

9.29%

Increased from previous period

BV/share growth of 9.29% while TRAW is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.

Debt Growth

10.32%

Increased from previous period

Debt growth of 10.32% while TRAW is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.

R&D Expense Growth

No Data

No Data available this quarter, please select a different quarter.

SG&A Expenses Growth

402.37%

Increased from previous period

SG&A growth of 402.37% while TRAW is zero. Bruce Berkowitz sees more spend on admin or marketing, expecting stronger top-line in return.

+ Add New Metric (Coming Soon)

Add more metric or remove existing ones, customize as per your preference, feature coming soon!

Select Chart Metric:

ATNM Financial Growth Analysis - Compare Against TRAW

Comparison against TRAW

None AGEN AVXL RVPH AXSM TRAW

Revenue Growth

No Data

No Data available this quarter, please select a different quarter.

Gross Profit Growth

No Data

No Data available this quarter, please select a different quarter.

EBIT Growth

-2634.20%

Decreased from previous period

Negative EBIT growth while TRAW is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.

Operating Income Growth

-468.26%

Decreased from previous period

Negative operating income growth while TRAW is at 0.00%. Joel Greenblatt would press for urgent turnaround measures.

Net Income Growth

-263.73%

Decreased from previous period

Negative net income growth while TRAW stands at 0.00%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.

EPS Growth

-197.18%

Decreased from previous period

Negative EPS growth while TRAW is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.

Diluted EPS Growth

-197.18%

Decreased from previous period

Negative diluted EPS growth while TRAW is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.

Share Count Growth (Basic)

22.83%

Share change of 22.83% while TRAW is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.

Share Count Growth (Diluted)

22.83%

Diluted share change of 22.83% while TRAW is zero. Bruce Berkowitz might see a minor difference that could widen over time.

Dividend per Share Growth

No Data

No Data available this quarter, please select a different quarter.

Operating Cash Flow Growth

-36.01%

Decreased from previous period

Negative OCF growth while TRAW is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.

Free Cash Flow Growth

-62.21%

Decreased from previous period

Negative FCF growth while TRAW is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.

10-Year Revenue Growth per Share (CAGR)

No Data

No Data available this quarter, please select a different quarter.

5-Year Revenue Growth per Share (CAGR)

No Data

No Data available this quarter, please select a different quarter.

3-Year Revenue Growth per Share (CAGR)

No Data

No Data available this quarter, please select a different quarter.

10-Year Operating Cash Flow Growth per Share

-319.11%

Decreased from previous period

Negative 10Y OCF/share CAGR while TRAW stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.

5-Year Operating Cash Flow Growth per Share

-319.11%

Decreased from previous period

Negative 5Y OCF/share CAGR while TRAW is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.

3-Year Operating Cash Flow Growth per Share

52.30%

Increased from previous period

3Y OCF/share CAGR of 52.30% while TRAW is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.

10-Year Net Income Growth per Share

-5305.80%

Decreased from previous period

Negative 10Y net income/share CAGR while TRAW is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.

5-Year Net Income Growth per Share

-5305.80%

Decreased from previous period

Negative 5Y net income/share CAGR while TRAW is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.

3-Year Net Income Growth per Share

-47.53%

Decreased from previous period

Negative 3Y CAGR while TRAW is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.

10-Year Shareholders’ Equity Growth per Share

-1146.88%

Decreased from previous period

Negative equity/share CAGR over 10 years while TRAW stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.

5-Year Shareholders’ Equity Growth per Share

-1146.88%

Decreased from previous period

Negative 5Y equity/share growth while TRAW is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.

3-Year Shareholders’ Equity Growth per Share

3.51%

Increased from previous period

Equity/share CAGR of 3.51% while TRAW is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.

10-Year Dividend per Share Growth (CAGR)

No Data

No Data available this quarter, please select a different quarter.

5-Year Dividend per Share Growth (CAGR)

No Data

No Data available this quarter, please select a different quarter.

3-Year Dividend per Share Growth (CAGR)

No Data

No Data available this quarter, please select a different quarter.

Receivables Growth

-100.00%

Firm’s AR is declining while TRAW shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.

Inventory Growth

No Data

No Data available this quarter, please select a different quarter.

Asset Growth

No Data

No Data available this quarter, please select a different quarter.

Book Value per Share Growth

9.29%

Increased from previous period

BV/share growth of 9.29% while TRAW is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.

Debt Growth

10.32%

Increased from previous period

Debt growth of 10.32% while TRAW is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.

R&D Expense Growth

No Data

No Data available this quarter, please select a different quarter.

SG&A Expenses Growth

402.37%

Increased from previous period

SG&A growth of 402.37% while TRAW is zero. Bruce Berkowitz sees more spend on admin or marketing, expecting stronger top-line in return.

+ Add New Metric (Coming Soon)

Add more metric or remove existing ones, customize as per your preference, feature coming soon!

Select Chart Metric: